The results showed that after STC2 was used to treat the two breast cancer cell lines, Bax protein expression levels were significantly upregulated, and cleaved PARP protein expression levels were also upregulated to varying degrees (Figures 4(e) and 4(f)). This evidence concerns the gene BAX and breast cancer.